Engel Michael, Hoffmann Torsten, Wagner Leona, Wermann Michael, Heiser Ulrich, Kiefersauer Reiner, Huber Robert, Bode Wolfram, Demuth Hans-Ulrich, Brandstetter Hans
Max-Planck-Institut für Biochemie, Abt. Strukturforschung, D-82152 Martinsried, Germany.
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5063-8. doi: 10.1073/pnas.0230620100. Epub 2003 Apr 10.
The membrane-bound glycoprotein dipeptidyl peptidase IV (DP IV, CD26) is a unique multifunctional protein, acting as receptor, binding and proteolytic molecule. We have determined the sequence and 1.8 A crystal structure of native DP IV prepared from porcine kidney. The crystal structure reveals a 2-2-2 symmetric tetrameric assembly which depends on the natively glycosylated beta-propeller blade IV. The crystal structure indicates that tetramerization of DP IV is a key mechanism to regulate its interaction with other components. Each subunit comprises two structural domains, the N-terminal eight-bladed beta-propeller with open Velcro topology and the C-terminal alpha/beta-hydrolase domain. Analogy with the structurally related POP and tricorn protease suggests that substrates access the buried active site through the beta-propeller tunnel while products leave the active site through a separate side exit. A dipeptide mimicking inhibitor complexed to the active site discloses key determinants for substrate recognition, including a Glu-Glu motif that distinguishes DP IV as an aminopeptidase and an oxyanion trap that binds and activates the P(2)-carbonyl oxygen necessary for efficient postproline cleavage. We discuss active and nonactive site-directed inhibition strategies of this pharmaceutical target protein.
膜结合糖蛋白二肽基肽酶IV(DP IV,CD26)是一种独特的多功能蛋白,兼具受体、结合和蛋白水解分子的作用。我们已确定了从猪肾制备的天然DP IV的序列及1.8埃的晶体结构。晶体结构揭示了一种2-2-2对称的四聚体组装形式,该形式依赖于天然糖基化的β-螺旋桨叶片IV。晶体结构表明,DP IV的四聚化是调节其与其他成分相互作用的关键机制。每个亚基包含两个结构域,即具有开放维可牢拓扑结构的N端八叶片β-螺旋桨结构域和C端α/β-水解酶结构域。与结构相关的POP和三触角蛋白酶的类比表明,底物通过β-螺旋桨通道进入埋藏的活性位点,而产物则通过一个单独的侧出口离开活性位点。与活性位点复合的二肽模拟抑制剂揭示了底物识别的关键决定因素,包括区分DP IV作为氨肽酶的Glu-Glu基序以及结合并激活脯氨酸后有效切割所需的P(2)-羰基氧的氧阴离子阱。我们讨论了这种药物靶蛋白的活性和非活性位点导向抑制策略。